A meta-analysis confirmed significantly reduced risk for ovarian cancer for BRCA1 (SRR = 0.51; 95% CI 0.40–0.65) and BRCA2 mutations carriers (SRR = 0.50; 95% CI 0.29–0.89) associated with use of OC. The gene discussed is BRCA2; the disease is ovarian cancer.